OpGen Reports First Quarter 2023 Financial Results and Provi

15.05.2023 - Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero ...

Related Keywords

Ukraine , Russia , China , Chinese , Curetis Gmb , Oliver Schacht , Edison Group , Technology Platform , Foundation For Innovative New Diagnostics , European Investment Bank , Financial Results Of Opgen Inc , International Number , Securities Exchange , Gene Panel , Exchange Commission , Opgen Inc , Opgen Investor Press Contact , Ares Genetic , Fisher Healthcare , Innovative New , Unyvero Urinary Tract Infection , Thermo Fisher , Ares Genetics , Dial In Number , United Statesa , Curetis Gmbh , Ares Genetics Gmbh , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Gen Investor , Press Contact ,